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Summary- The efficacy of tricyclics and benzodiazepines in the short term (approximately 2 4 
months) trcatmcnt of panic disorder is well demonstrated, but ellicacy o\‘cr the longer term is not 
considered established. The present study provided systematic data from a double blind comparison 
of maintenance therapy (up to 8 months) of panic disorder- wjith or without agoraphobia with 
alprazolam, imipramine, or placebo in 181 patients who had responded to the same regimen in a 
randomized X-week trcatmcnt trial. All three groups had tmproved during the first 7 months (active 
treatments more than placebo and about equal to each other). and all maintained or cxtcnded their 
improvement over the next 6 months without any significant change in dose. More than twice as 
many alpraaolam and imipramine than placebo patients (15’%,) remained in treatment for the full 
8 months and did slightly better on symptom measurcs than the remaining placebo patients. Both 
medications were well tolerated during the maintenance period. The data suggest sustained efficacy 
and safety of imipramine and alprazolam over an cxtcndcd period. More specifically, they suggest 
that tolcrancc does not develop to the therapeutx efLccts of either drug. 
Introduction 
TRI~YCLIV “antidepressants” (Ballenger, 1986; Liebowitz, 1985) and benzodiazepines (Bal- 
lenger, 1990; Ballenger et al., 1988; Cross-National Collaborative Panic Study Second Phase 
Investigators, 1992) have been found to be safe and effective in the acute treatment of panic 
disorder; i.e., up to about 8 weeks. The most extensively studied compounds are the tricyclic 
imipramine and the benzodiazepine alprazolam. For initiation of therapy, most of the 
advantage appears to lie with alprazolam, since its onset of therapeutic action is more rapid, 
and initial side effects are fewer and less troublesome. Within a month or less, however, the 
therapeutic effects of imipramine catches up, so that effectiveness is then about equal. 
Tricyclic side effects also appear to abate somewhat with time. Beyond the acute phase of 
drug treatment, i.e., the tirst month or two. there are many questions and little systematic 
data. 
Questions concerning therapy over the longer term concern four main issues. The first 
concerns the natural history of the illness, and whether maintenance therapy is indicated 
at all. It does appear that in at least some cases the illness is chronic, and that in such cases 
maintenance therapy may be indicated (Noyes et al., 1990; Pollack et al., 1990). The second 
issue concerns withdrawal or rebound symptoms when drug treatment is stopped. It is now 
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clear that some such effects attend discontinuation of either class of compounds, but appear 
to be more troublesome in the case of benzodiazepines (Pecknold, Swinson, Kuch, & Lewis, 
1988; Rosenberg, 1990). It is not clear whether severity of drug discontinuation effects are 
related to duration of therapy. The third issue concerns whether additional side effects 
occur during maintenance therapy, and the fourth is whether therapeutic effectiveness is 
stable over time, or more specifically, whether tolerance develops to the therapeutic effects. 
This report deals with the latter two issues; i.e., efficacy and side effects over the longer 
term in a large multicenter trial of imipramine, alprazolam, and placebo. Data from that 
trial pertaining to short term effects (Cross-National Collaborative Panic Study Second 
Phase Investigators, 1992), drug discontinuation effects (Rosenberg, 1990), and relapse and 
long term outcome (Katschnig, 1990) are reported elsewhere. 
Such documentation as is currently available on efficacy and side effects during main- 
tenance therapy is mostly retrospective in nature, coming from follow-up of patients l-6 
years after initial treatment in acute study protocols, followed by naturalistic treatment 
until the time of follow-up (Aronson, 1989; Katschnig, 1990; Nagy, Krystal, Woods & 
Charney, 1989; Noyes et al., 1988, 1990; Pollack, Tesar, Rosenbaum, & Spier, 1986). At 
follow-up a high proportion of patients are usually found to have remained on medication, 
frequently at reduced dose, to have maintained or extended their improvement and to have 
tolerated continued medication therapy quite well for extended periods of time. In these 
studies, however, the effects of multiple treatments are difficult to separate, and systematic 
information on clinical condition and medication doses during the course of maintenance 
therapy is usually not available. In a study by Burrows (1990), patients with panic disorder 
on maintenance therapy with alprazolam were reported to tolerate the treatment quite well 
and to maintain their improvement without escalation of dose. The present study has several 
features apparently not reported elsewhere. Patients from an acute treatment study were 
maintained on the same double blind treatment with either alprazolam, imipramine or 
placebo for a total of 8 months, while all other treatments were excluded, and systematic 
data collection was carried out at monthly intervals. 
Data for the study were obtained during the Cross-National Collaborative Panic Study, 
Phase II, sponsored by the Upjohn Company, Kalamazoo, Michigan. The Cross-National 
trial was conducted in two phases. In Phases I and II, alprazolam was superior to placebo 
in an 8-week acute treatment period (Ballenger et al., 1988; Cross-National Collaborative 
Panic Study Second Phase Investigators, 1992). Both drugs were well tolerated (Cassano. 
1990; Noyes et al., 1988), but discontinuation of alprazolam was accompanied by a transient 
symptom rebound in S&27% and withdrawal symptoms in approximately 35% of patients 
despite gradual reduction in dose (Pecknold et al., 1988; Rosenberg, 1990). Phase I patients 
whose treatment periods were extended from 24 to 52 weeks maintained their improvement, 
with a slight reduction (rather than an increase) in average dose (Burrows, 1990). In Phase 
II imipramine was also superior to placebo during the initial 8 weeks and approximately 
equal to alprazolam on most measures, but alprazolam had a more rapid onset of action, 
fewer side effects and fewer dropouts (Cross-National Collaborative Panic Study Second 
Phase Investigators, 1992). 
Four of the 12 Phase II study sites participated in a study of maintenance drug therapy 
for 6 additional months following the initial 2-month acute treatment period. 
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Methods 
The design and methods of the overall Cross-National Collaborative Panic Study have 
been described in detail elsewhere (Klerman, 1988; Klerman, Coleman, & Purpura, 1986). 
Briefly, there were two phases. Phase I was a multicenter randomized, double blind, flexible 
dose trial of alprazolam versus placebo in the treatment of panic disorder with or without 
agoraphobia, providing data from 481 patients (Ballenger et al., 1988). Phase II employed 
similar methods and design, but included an imipramine cell in addition to the alprazolam 
and placebo cells, and provided data on 1,010 patients in the acute treatment study. 
Phase II was conducted at 12 sites in Western Europe, South America, and North 
America. Patients with a history of DSM-III major depression beginning prior to the onset 
of panic disorder were excluded. Diagnoses were arrived at by the Structured Clinical 
Interview for DSM-III (SCID), modified for this project (SCID-UP). A flexible dosing 
schedule was employed with adjustments according to tolerance and judged therapeutic 
need. Maximum dose was 10 tablets per day, representing 10 mg of alprazolam or 225 mg 
of imipramine. Change measures reported here include drug dose, retention in the study, 
total number of panic attacks per week, overall phobia score, Hamilton Anxiety Scale, and 
Physicians’ global improvement ratings. 
Patients at four selected study sites (Belgium, Brazil, Italy and Spain), who completed 
the acute phase were invited to continue the same double blind treatment for an additional 
6 months if they were judged to have benefited from their treatment to that point. A total 
of 181 patients accepted the invitation and entered this phase of the study: 78 were on 
alprazolam, 65 on imipramine, and 38 on placebo, representing 58.2%, 47.1%, and 27.3%, 
respectively, of the patients entering the acute treatment study from those sites. Patients 
were seen monthly. Clinical assessments, ratings, and dose adjustments under double blind 
conditions were conducted as in the acute study. 
Extensive testing had indicated good randomization of the initial 1,010 patients. Since 
patients entering the maintenance therapy trial were a selected subset of the initial ran- 
domized sample, additional tests were performed to evaluate the representativeness of 
the maintenance therapy sample with respect to the original randomized sample and the 
comparability of the three maintenance therapy groups to each other. Patients from the 4 
sites who did and did not subsequently enter the maintenance treatment trial were compared 
at baseline prior to any treatment and again at the end of acute treatment (week 8). Then, 
patients in the alprazolam, imipramine and placebo groups who entered the maintenance 
therapy study were compared with each other at baseline prior to any treatment, and again 
at the end of acute treatment (week 8). Variables used for these comparisons included 
(where applicable) study site, treatment assignment, age, sex, panic disorder subtype 
(uncomplicated, limited avoidance, extensive avoidance), duration of illness, presence of 
current or past major depression, total panic attacks per week, anticipatory anxiety intensity, 
percentage of time spent in anticipatory anxiety, overall phobia severity, SCL-90 total score, 
Hamilton Anxiety, Hamilton Depression, ratings of work and social disability, medication 
dose, and physicians’ global improvement ratings. Adverse effects were assessed using a 
modification of SAFTEE, which was developed at the NIMH Psychopharmacology 
Research Branch (Levine & Schooler, 1986). Also, the physician prepared a descriptive 
report of any intercurrent illnesses or medical events which were considered clinically 
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significant, whether or not they were thought to be drug related. These reports included the 
time of onset, actions taken if any, and a judgment of whether the event was drug related. 
To compare across treatments during maintenance therapy, and across time within 
treatments, only descriptive statistics (central tendency and error of estimate) were per- 
formed on measures of change. This limitation was observed because the patients entering 
the maintenance treatment study were no longer strictly randomized groups, and thus did 
not satisfy conventional requirements for performing comparative statistics. On the other 
hand, the comparability of the different drug groups to each other and their repre- 
sentativeness of the total randomized samples on important clinical variables were known 
and did not appear to be significantly biased except with respect to the response to their 
assigned treatment. By inspection of graphic displays of means and 95% confidence inter- 
vals, it was possible to estimate which differences would have been significant if comparative 
statistics had been carried out. 
Results 
Adequacy of randomization 
By far the largest differences between patients who did and did not enter the maintenance 
treatment study were the site of study and the treatment assignment, both being highly 
significant statistically. As is shown in Tables 1 and 2, more patients in Italy and Brazil and 
fewer in Belgium entered the extended study. Reasons for the site differences were not 
entirely clear, but they appeared to relate to different patient management styles and 
different practice conditions in the countries. Also, more patients assigned to alprazolam 
than to imipramine entered the maintenance therapy study, and far more assigned to either 
active treatment than to placebo entered. 
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Note. ITT = intent-to-treat. 
anticipatory anxiety intensity, which was slightly but significantly higher in those who 
entered, and Hamilton Anxiety and Hamilton Depression scores which were slightly but 
significantly higher in those who did not enter. The entry and non-entry groups did not 
differ significantly at baseline on any of the other comparison variables. 
As intended, at the end of the acute treatment (week g), patients who entered the 
maintenance therapy study were in better clinical condition than those who did not, as 
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Table 2 











134 78 58.2% 
138 65 47.1% 
139 38 27.3% 
411 181 44.0% 
Chi-square = 27.2 p = ,000 
Note. ITT = intent-to-treat. 
indicated by fewer total panic attacks per week, and by lower scores on overall phobia, 
anticipatory anxiety intensity, total SCL-90, Hamilton Anxiety, Hamilton Depression, and 
work and social disability, and physicians’ ratings of global improvement. All differences 
were highly- significant statistically, p values ranging from < .Ol to < .OOOl. No other 
differences between the groups were significant at this point in time. 
At pre-acute phase baseline, only one marginally significant (p = ,053) difference was 
detected among the alprazolam, imipramine and placebo groups entering the maintenance 
study. This was in the mean total SCL-90 score, the placebo group being slightly lower 
than the active treatment groups. 
At the end of the acute treatment period (week 8), the active treatment groups entering 
the maintenance therapy study were significantly better than the placebo group with respect 
to anticipatory anxiety intensity, overall phobia, Hamilton Anxiety, and physicians’ global 
improvement ratings. Since none of these differences were present prior to treatment, the 
findings suggest that, although only patients who had improved were invited to continue, 
the patients on active treatments had improved somewhat more than those on placebo. 
Dropouts before and during maintenance therapy 
Figure 1 graphs the percentage of patients, with 95% confidence intervals, from the 4 
study sites combined, who remained in the study at each time point from the acute phase 
baseline through the final maintenance therapy evaluation at month 8 of the study. Points 
where 95% confidence intervals do not overlap represent statistically significant differences. 
At month 2, the end of the acute treatment study, the alprazolam group had a significantly 
higher retention rate (84%) than either the imipramine (68%) or placebo groups (62%). 
From that point on, the difference between alprazolam and imipramine narrowed and, at 
the end, essentially identical percentages of patients in the alprazolam group (37% of those 
randomized, 61% of those entering maintenance) and in the imipramine group (35% of 
those randomized, 74% of those entering maintenance) remained in the study. Both active 
treatment groups retained significantly more patients throughout the maintenance therapy 
study than did the placebo group, in which only 15% of the initial randomized sample 
(55% of those entering maintenance) completed the maintenance therapy study. 
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Figure 1. Retention in study with 95% confidence levels. ITT = intent-to-treat. APBL = acute phase baseline. 
Month 2 = end of acute phase. EMP = enter maintenance phase. 
Stability of dew 
At each visit the clinician had the option of adjusting the medication dose if the clinical 
condition of the patient so indicated. Figure 2 graphs the average number of tablets taken 
per day from beginning to end of the maintenance therapy study. The doses were essentially 
identical and unchanging at between 6 and 7 tablets per day, representing either that number 
of placebo tablets, or 6 or 7 mg of alprazolam, or 150 or 175 mg of imipramine per day. If 
comparative statistics had been performed, there would have been no significant differences 
between medication groups at any time point and no significant changes with time in any 
medication group. 
Figure 3 graphs total number of panic attacks per week with 95% confidence intervals 
from the acute study baseline to the end of the maintenance therapy study. Plots for the 
groups are presented separately rather than superimposed because some of the information 
is obscured in the superimposed plots. It appears that if comparative statistics had been 
performed, there would have been no significant differences between treatment groups from 
beginning to end of the maintenance therapy study. However. the very wide confidence 
intervals in the placebo group indicates that some patients continued to have significant 
numbers of panic attacks, whereas virtually no attacks occurred from month 4 onward 
among patients remaining in the imipramine group, as indicated by near-zero means and 
near-zero 95% confidence intervals. Patients in the alprazolam group continued to have 
infrequent attacks. The endpoint values are the mean and confidence intervals of the last 
value obtained for all subjects in the maintenance therapy study, regardless of whether they 
dropped out prior to the end or remained until the end. The relatively large differences in 
mean and confidence interval between month 8 and the endpoint in the placebo group 
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Figure 2. Average number of tablets per day with 95% confidence intervals. 
suggests a trend for patients who dropped out to have been having more panic attacks at 
the time of dropout than completers were having at the time of completion. 
Figure 4 graphs overall global phobia scores. Comparative statistics would probably have 
indicated no significant differences between groups or within groups over time. However, the 
somewhat higher means and wider confidence intervals in the placebo group suggest that 
some placebo patients did relatively poorly on this measure compared to the other groups. 
The comparatively large difference between month 8 and endpoint for the placebo group 
again shows that placebo dropouts tended to be more symptomatic at the time of dropout 
than were completers at the time of completion. 
Figure 5 graphs means and 95% confidence intervals of Hamilton Anxiety Scale scores. 
Comparative statistics would probably have indicated few or no differences between treat- 
ments at any time point. However, the early and late confidence intervals of imipramine 
subjects sometimes fail to overlap, suggesting the possibility of a slight continuing improve- 
ment from early to late maintenance therapy. Again, the placebo group showed a somewhat 
greater difference between endpoint and completer values. 
Figure 6 graphs means and 95% confidence intervals of physicians’ global improvement 
scores. Placebo patients did somewhat less well throughout the maintenance therapy study, 
but only occasionally did the 95% confidence intervals fail to overlap those of the active 
treatment groups. Alprazolam and imipramine confidence intervals usually overlapped. 
Over time the alprazolam group remained stable, but in the imipramine group, early and 
late confidence intervals sometimes failed to overlap, suggesting possible slight continuing 
improvement in the imipramine group. Some apparent improvement may have been due 
to dropping out by patients who were doing less well. This effect appears to have been 
smaller in the active treatment groups than in the placebo group, judging by the difference 
between week 8 and endpoint scores. 
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Figure 4. Overall global phobia ratings with 95% confidence intervals. 
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Figure 5. Hamilton Anxiety Scale with 95% confidence intervals. 
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Figure 6. Physicians’ global improvement with 95% confidence levels. 
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Unwanted eflects during maintenunce therapy 
Side effects were minor and infrequent in all groups. Table 3 lists the percentage of 
patients in whom the most frequent unwanted effects were found in at least one visit during 
the maintenance therapy study. In order to provide documentation without excessive minor 
detail, Table 3 includes only those symptoms which were found at least once at an intensity 
higher than at short term baseline in at least 10% of the patients in an active treatment 
group, provided that the frequency of that finding was higher in that active treatment group 
than in the placebo group. Notably, 83% of placebo patients had at least one such symptom 
on at least one visit. This exceeded the frequency for both the alprazolam (80%) and the 
imipramine (74%) groups. 
Abnormal diastolic blood pressure 23 
Abnormal weight change 22 
Weight loss 21 




Dry Mouth 12 
Tremor I 0 
Nausea/vomiting II 
Constipation 20 
Any side effect 80 
Any medical event 21 

























Note. Items from a lisl of 46 are included if the symptom occurred in at least 10% of patients 
on either active drug and if that figure also exceeded the percentqe for placebo. Abnormal 
diastolic pressure delined as 290 mm Hg. Abnormal weight change defined as t 5% change 
from short term baseline. Medical events included pregnancy. transient fevers. psychiatric 
symptoms, intercurrent illnesses, etc. 
In the imipramine group the frequency of most side effects was less than in either the 
placebo or the alprazolam group, with the exception of increased appetite (19% of patients), 
and abnormal weight change (36%). Even constipation, which is a recognized side effect of 
imipramine was reported less (12%) than in the alprazolam group (20%) though more than 
in the placebo group (3%). Dry mouth, perhaps the most common early side effect of 
imipraminc therapy, was not among the more frequently reported side effects, being reported 
at least once during the maintenance therapy study by 12% of alprazolam patients and 
only 3% 0 f imipramine and placebo patients. The following symptoms were found as 
described in 10% or more of one or the other treatment groups but were omitted from 
reporting because they were found in a higher percentage of placebo patients: dizzi- 
ness/faintness, headache, stomach/abdominal discomfort, decrease in appetite, and weight 
gain. 
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Discussion 
These results clearly indicate that initial therapeutic gains with imipramine or alprazolam 
are sustainable by maintenance therapy for periods up to at least 8 months, without the 
need for dose escalation, and without serious development of side effects. This is consistent 
with conclusions based on retrospective naturalistic follow-up studies (Aronson, 1989; 
Katschnig, 1990; Nagy et al., 1989, 1990; Noyes, Garvey, Cook, & Samuelson, 1989; Pollack 
et al., 1986) and with data collected during maintenance therapy with alprazolam or placebo 
from a subset of patients from Phase I of the Cross-National Collaborative Study (Burrows, 
1990). The problem is, that from the present study the same could be said of placebo 
treatment. However, because of the pattern of dropouts, things are not quite that simple. 
Unfortunately, reasons for dropouts were not recorded during the maintenance study. 
In the immediately preceding acute treatment study the most common reasons given for 
dropouts were ineffectiveness of medication, side effects, and patients refusing treatment 
for reasons not specified (Cross-National Collaborative Panic Study Second Phase Inves- 
tigators, 1992). In that study and in the present one, mean endpoint values (last value 
obtained from every patient) were rather consistently worse than mean completer values 
(last value of all patients completing the study), suggesting that dropouts were doing less 
well than completers. All of this is consistent with the common sense inference that not 
doing well may be a major reason for dropping out. To the extent that this is the case, 
dropouts will inflate the apparent efficacy of all treatments, both active and inactive. Also, 
to the extent that this is true, more dropouts mean more inflation. In this study, the retention 
rate of the placebo group was only about half that of the active treatment groups, suggesting 
that apparent placebo improvement was more inflated than apparent improvement on 
alprazolam or imipramine. Even so, the remaining alprazolam and imipramine patients did 
slightly better than placebo patients on most measures, though only occasionally the 95% 
confidence intervals failed to overlap. Thus it is at best dubious to conclude that placebo 
was actually as effective for maintenance therapy as alprazolam or imipramine. 
It is much harder to identify any advantage of one of the active drugs over the other. 
For the first 24 weeks of treatment, alprazolam appeared to be more effective and have 
fewer side effects than imipramine (Cross-National Collaborative Panic Study Second Phase 
Investigators, 1992; Ballenger et al., 1988). Thereafter, the advantage narrowed, and in the 
present study, appeared to be completely gone by 8 months. In fact there were slight hints 
of a trend favoring imipramine during the final months of the maintenance study. 
Another limitation of the study is that the groups entering the maintenance therapy study 
were no longer randomized, but emerged by self- and clinician-selection from groups which 
had been randomized for the purpose of the acute treatment study. Selection was primarily 
based on improvement and tolerance for their assigned treatments, though unidentified 
factors operating locally at the study sites also clearly played a large role. Nevertheless the 
selection process did not appear to bias or unbalance the treatment samples in any obvious 
or very significant way detectable by conventional tests for adequacy of randomization. 
The findings in the imipramine group are consistent with other reports (Aronson, 1989; 
Noyes et al., 1989) suggesting that around 35-50% drop out early, primarily because of 
side effects, but that those who remain improve and maintain their improvement for periods 
of months to years. However, Aronson’s patients received behavior therapy at the beginning, 
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and this could have had some part in maintenance of improvement. This was not a factor 
in the present study, since all formal psychotherapies were excluded while drug treatment 
was in progress. Apparently the main problem with imipramine early in treatment is 
overstimulation, and the main problem later is weight gain. Some of the early troublesome 
anticholinergic side effects of imipramine, specifically dry mouth and constipation, appear 
to wane with prolonged treatment, either as a result of tolerance or of dropout. 
For the design of future studies the main points of improvement would be preserving the 
randomization, and reducing the attrition and keeping careful account of reasons for 
dropouts. Trials over longer periods of time with long follow-up intervals are also desirable 
but difficult to implement. Part of preserving the randomization could be accomplished 
simply by enrolling patients with the understanding that the study is to be a long-term one. 
Early dropouts from tricyclic treatment can probably be reduced by a slower dosage 
buildup. Maintaining placebo groups over long periods of time is probably not feasible. If 
the dropout rate cannot be reduced, it can at least be used as an outcome measure, with a 
clearer determination of the reasons for dropout than was done in the present study. The 
pros and cons of endpoint versus completer analyses for the statistical handling of dropouts 
has been discussed elsewhere (Cross-National Collaborative Panic Study Second Phase 
Investigators, 1992). In addition to the traditional endpoint and completer analyses, it 
might also be helpful for clinicians if further analyses were conducted of data from only 
those patients who complete the study. This is traditionally not done because the completers 
are considered not representative of the initially randomized group. However, this is the 
only way of knowing what actually happens to patients who actually stay with a particular 
treatment. Such information is not accurately reflected by the present practice of reporting 
and analyzing mean scores of a group which diminishes in size at each time point, since 
this provides no exact measure of the initial scores of those patients who completed the 
study, and are consequently the only ones whose scores are available at the final time point. 
Conclusions 
These results suggest that in cases where long-term treatment is needed, either alprazolam 
or imipramine may be a viable option. On average, as far as efficacy, patient acceptance, 
and safety while on medication are concerned, there appears to be little basis for choosing 
either of these two drugs over the other. Such faint and uncertain advantages as there may 
be, appear slightly to favor imipramine. Ease of discontinuation also favors imipramine, 
though discontinuation of alprazolam is also quite manageable if one employs patience and 
understands the principles involved (Abelson & Curtis, 1993). Of great potential importance 
is the recent report (Mavissakalian & Perel, 1992) that after 6 months on imipramine, 
relapse can be prevented for up to an additional year by maintenance on half the original 
dose. Whether the same is possible with benzodiazepines remains to be determined. Since 
the advantages of one agent are mostly at the beginning of treatment, and the advantages 
of the other seem to be mainly over the longer term, one naturally thinks of either starting 
both together and later tapering away the alprazolam, or of starting with alprazolam, 
adding imipramine later and then tapering the alprazolam. This does seem to work in the 
hands of some clinicians, though the time required for tapering the alprazolam may be 
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longer than anticipated. As in all clinical decisions, factors specific to individual patients 
may outweigh other considerations. For example tricyclics must be avoided in patients with 
heart block and may be problematic in elderly patients or in patients on other drugs with 
anticholinergic side effects. Benzodiazepines may be problematic in patients with histories 
of alcohol or drug abuse. The dose of alprazolam (average about 6.5 mg/day, maximum 
10 mg/day) was higher than the maximum of 4 mg/day currently recommended in the 
United States, but similar to those required in the acute studies preceding this one (Ballenger, 
1990; Ballenger et al., 1988; Cross-National Collaborative Panic Study Second Phase 
Investigators, 1992). The higher doses are well tolerated when needed for symptom control. 
The currently recommended doses in the United States appear to be too low for optimal 
effectiveness. A number of other countries do recommend doses of up to 10 mg/day. 
A question of major interest is how long drug therapy should be continued. This question 
cannot be answered as clearly as it can be for depression, because the necessary work has 
not yet been done. About as much as one can say at present is that the relapse rate appears 
to be high after acute drug trials and the illness appears to be chronic, perhaps lifelong, in 
some patients. A reasonable approach would seem to be to treat with drugs until both 
patient and therapist are comfortable that stable symptom control has been achieved. Then 
with the patient’s agreement, a search can be initiated for the minimum dose which controls 
symptoms. In the case of benzodiazepines, patient and therapist must both understand that 
a temporary period of rebound anxiety may follow each dose reduction. Partial relapses 
may be treatable with cognitive/behavioral methods. Using an approach similar to this, 
Abelson and Curtis (1993) found 78% of their alprazolam treated patients could discontinue 
benzodiazepines and that only 36% of those relapsed. Some 1 to 2 years after enrollment, 
61% of those followed up were medication free. However, the taper period occasionally 
lasted up to 18 months. 
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